Printer Friendly

Xeotron Announces Establishment of Illustrious Scientific Advisory Board.

Business Editors/Health & Medical Writers

BIOWIRE2K

HOUSTON--(BW HealthWire)--Oct. 31, 2001

Xeotron Corporation today announced the formation of its scientific advisory board comprised of four of the world's most preeminent experts in genomics and related fields. The company develops and manufactures high-performance, inexpensive BioChips that provide major advantages in quality, cost, flexibility and quick turn-around based on a novel and proprietary technology platform combining photochemistry, digital photonics and microfluidics.

The newly appointed advisory board members are:

George Church, Ph.D., professor, director of the Lipper Center for Computational Genetics, Harvard Medical School; David G. Wang M.D., Ph.D., executive vice president of strategy, technology and operations, First Genetic Trust Inc.; and C. Thomas Caskey, M.D., president and chief executive officer of CoGene Biotech Ventures, Ltd. They will join Xiaolian "Lian" Gao, Ph.D., a co-founder of Xeotron who currently serves as the company's chief scientific officer.

"We are both honored and privileged that this renowned and distinguished group is contributing their expertise in support of our efforts in becoming the premier microchip technology for use across the life sciences spectrum to improve patient care," said Martin Lindenberg, M.D., chairman and CEO, Xeotron Corp. "Their participation is another important milestone in the growing success of Xeotron and further confirms the confidence in our novel technology platform."

Xeotron is the first company to combine three well-proven sciences -- digital photonics, microfluidics and photochemistry -- which are at the core of its proprietary technology platform, to address the growing demands of the BioChip market. This has resulted in open-architecture, high-performance BioChips that change the landscape of biological discovery. Xeotron's BioChips enable very rapid discovery cycles because they are faster from design to use, more cost-effective and consume low-sample volume, while providing high-quality performance and accuracy. Importantly, researchers and drug companies can use Xeotron's BioChips on existing equipment, dramatically lowering entry costs and increasing the number of users. Xeotron's advanced customizable microchips set new standards because they are not burdened by the problems of expense, time and lack of versatility in chips made by other companies.

"Our highly versatile DNA, RNA and peptide chips offers a broad range of applications for genomics and proteomics research, drug discovery and development and diagnostics," Dr. Lindenberg added. "Our low cost of entry for users (saving over $100,000 entry fees compared to other systems) makes it possible for both academic institutions and major companies to quickly adopt biochips in their laboratories to enhance throughput and accelerate life-saving research and development."

The BioChip market currently stands at about $600 million annually and is expected to swell to approximately $3 billion for DNA chips alone and to $5 billion or more with RNA and peptide chips over the next few years.

Xeotron recently (May 2001) completed a $9 million Series A financing, with Vanguard Ventures of Houston, and Palo Alto, Calif., as the lead investor. Xeotron's science and technology, along with its founding scientists, have been awarded the highest honors at the leading biotechnology research conferences. The company is in the early stages of commercialization of its initial DNA and peptide chips for characterizing cancer gene expression, HIV genotyping, human genome-scale expression profiling and for drug discovery and target validation. It plans on completing a Series B financing in early 2002 to support product development, and to expand production, sales and marketing.

Brief biographies of the Scientific Advisory Board:

George Church, Ph.D., professor, director of the Lipper Center for Computational Genetics, Harvard Medical School. Dr. Church is widely recognized for the development of the first direct genomic sequencing method and for inventing the broadly applied concepts of molecular multiplexing and tags, a homologous recombination method and an array DNA synthesizer. He also helped initiate the Human Genome Project. Dr. Church is a co-founder of the Stanford, MIT and Waltham Genome Centers and a former research scientist at Biogen Inc. and at UCSF. He also serves on the advisory boards of several biotechnology companies and scientific journals.

David G. Wang, M.D., Ph.D., executive vice president of strategy, technology and operations, First Genetic Trust Inc. Dr. Wang recently served as director of applied genomics and bioinformatics at Motorola Life Sciences and as chairman of the SNP Consortium's Scientific Management Committee. He was formerly head of human genetics at Bristol-Myers Squibb and also has conducted research at the Whitehead Institute/MIT Center for Genome Research.

C. Thomas Caskey, M.D., president and chief executive officer of CoGene Biotech Ventures, Ltd. Dr. Caskey also serves as an adjunct professor at the Baylor College of Medicine where he has held a variety of positions during his 25-year tenure there, including chairman of its Department of Human and Molecular Genetics and director of its Human Genome Center. He was formerly president of the Merck Genome Research Institute and senior vice president, human genetics and vaccines discovery at Merck Research Laboratories. He is a member of the National Academy of Sciences.

Xiaolian "Lian" Gao, Ph.D., a co-founder of Xeotron who currently serves as the company's chief scientific officer. Dr. Gao is also a professor of chemistry, biochemistry and biophysics at the University of Houston and was formerly senior scientist at Glaxo Inc. She is an internationally renowned expert and lecturer in nucleic acid chemistry, NMR, structural biological chemistry and combinatorial chemistry, and has published more than 60 scientific papers and received numerous awards in her field.

For more information contact Dr. Martin Lindenberg, chairman and CEO, 713/842-2121 (e-mail: mlintx@xeotron.com) or Marcia Katz, public relations, 516/220-6392 (e-mail: r.brode@worldnet.att.net) or visit www.Xeotron.com.
COPYRIGHT 2001 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Oct 31, 2001
Words:930
Previous Article:NRG Entertainment Inc. Announces New Director Don Grenough, Co-Founder of Herbalife.
Next Article:Image Entertainment Announces Nov. 27 DVD Release of I Spy: The Robert Culp Collection; Two Volumes Include Audio Commentary by Series Star Robert...


Related Articles
Comments on cabinet gene-splice plan.
Groups seek human gene-transfer delay.
Xeotron Develops High Throughput Technique for Creating Peptide Microchips; Findings Published in Peer Reviewed Journal Nature Biotechnology.
Xeotron Appoints Timothy McGrath as Chief Executive Officer.
A Presidential appointment.
George R. Pilcher, of Akzo Nobel, to deliver 2004 Mattiello Memorial Lecture in Chicago.
Secretary of the Air Force news release (March 22, 2005): Air Force announces new chief of Scientific Advisory Board.
2006 Arthur J. Dixon Award.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters